ID | 65974 |
JaLCDOI | |
フルテキストURL | |
著者 |
Horiguchi, Shigeru
Department of Gastroenterology and Hepatology, Okayama University Hospital
Matsumoto, Kazuyuki
Department of Gastroenterology and Hepatology, Okayama University Hospital
ORCID
Kaken ID
publons
Morimoto, Kosaku
Department of Gastroenterology and Hepatology, Okayama University Hospital
Matsumi, Akihiro
Department of Gastroenterology and Hepatology, Okayama University Hospital
Terasawa, Hiroyuki
Department of Gastroenterology and Hepatology, Okayama University Hospital
Fujii, Yuki
Department of Gastroenterology and Hepatology, Okayama University Hospital
Yamazaki, Tatsuhiro
Department of Gastroenterology and Hepatology, Okayama University Hospital
Tsutsumi, Koichiro
Department of Gastroenterology and Hepatology, Okayama University Hospital
ORCID
Kaken ID
researchmap
Kato, Hironari
Department of Gastroenterology and Hepatology, Okayama University Hospital
ORCID
Kaken ID
researchmap
|
抄録 | We investigated the effect of modified FOLFIRINOX (mFFX) in unresectable pancreatic cancer by retrospectively analyzing the cases of 43 patients who underwent BRCA testing (germline, n=11; somatic, n=26; both germline and somatic, n=6). The association between BRCA mutations and therapeutic effect was clarified. Six patients tested positive for germline pathogenic variants. Familial pancreatic cancer (33% vs. 3%, p=0.006) and peritoneal disseminated lesions (66% vs. 8%, p<0.001) were significantly more common in patients with germline pathogenic variants. The partial response (PR) rate was 100% in the germline BRCA-positive patients, and 27% in the germline BRCA-negative patients (p<0.001). The median progression-free survival (PFS) was not reached for any germline BRCA-positive patients but was 9.0 months for the germline BRCA-negative patients (p=0.042). Patients with stage IV BRCA-associated pancreatic cancer had better overall survival than those with non-BRCA-associated pancreatic cancer, although the difference was nonsignificant (not reached vs. 655 days, p=0.061). Our results demonstrate that a PR and prolonged PFS can be expected in germline BRCA-positive patients after treatment with mFFX. Our findings also suggest that germline BRCA pathogenic variants may be useful as biomarkers for the therapeutic effect of mFFX in patients with pancreatic cancer.
|
キーワード | BRCA
FOLFIRINOX
pancreatic cancer
progression-free survival
pathogenic variant
|
Amo Type | Original Article
|
出版物タイトル |
Acta Medica Okayama
|
発行日 | 2023-10
|
巻 | 77巻
|
号 | 5号
|
出版者 | Okayama University Medical School
|
開始ページ | 517
|
終了ページ | 525
|
ISSN | 0386-300X
|
NCID | AA00508441
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
著作権者 | Copyright Ⓒ 2023 by Okayama University Medical School
|
論文のバージョン | publisher
|
査読 |
有り
|
PubMed ID | |
Web of Science KeyUT |